

RECEIVED  
CENTRAL FAX CENTER  
NOV 02 2006

REMARKS

Claims 1, 2 and 4-12 are now in the application. Claims 1 and 2 have been amended to recite "a member selected from a group consisting of caffeine and theophylline" in place of "an antagonist of adenosine A1 receptor". Accordingly claims 8 and 9 have been amended in a similar manner to recite "said member selected from a group consisting of caffeine and theophylline" in place of "an antagonist of adenosine A1 receptor" and claims 10 and 11 have been amended by deleting "an antagonist of adenosine A1 receptor". Claims 1, 2 and 4-6 have been amended by deleting "a mixture of" and "and inorganic phosphate". Claims 4-11 have been amended to recite "and" between "1" and "2" for purposes of clarification and not to limit their scope.

The rejections of claims 1, 2, 4-9 and 12 under 35 USC § 112, first paragraph have been overcome by the above amendments to the claims whereby the terms "antagonist of adenosine A1 receptor" and "inorganic phosphate" have been deleted.

The rejection of claims 4-11 under 35 USC § 112, second paragraph has been overcome by the above amendment to these claims to recite "and" between "1" and "2".


In view of the above, consideration and allowance are, therefore, respectfully solicited.

In the event that the Examiner believes that an interview would serve to advance the prosecution of this application, the undersigned is available at the number noted below.

Please charge any fee due with this response to our Deposit Account No. 22-0185,  
under Order No. 21095-00008-US2 from which the undersigned is authorized to draw.

Dated: 11/2/06

Respectfully submitted,



Burton A. Amernick

Registration No.: 24,852

CONNOLLY BOVE LODGE & HUTZ LLP

1990 M Street, N.W., Suite 800

Washington, DC 20036

(202) 331-7111 (Phone)

(202) 293-6229 (Fax)

Attorney for Applicant